JP2004507208A5 - - Google Patents

Info

Publication number

JP2004507208A5

JP2004507208A5 JP2001561752A JP2001561752A JP2004507208A5 JP 2004507208 A5 JP2004507208 A5 JP 2004507208A5 JP 2001561752 A JP2001561752 A JP 2001561752A JP 2001561752 A JP2001561752 A JP 2001561752A JP 2004507208 A5 JP2004507208 A5 JP 2004507208A5

Authority

JP

Japan

Prior art keywords

seq

vegf

vegfr

amino acid

polypeptide

Prior art date

2001-02-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 claims description 502
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 428
• 229920001184 polypeptide Polymers 0.000 claims description 381
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 240
• 102000005962 receptors Human genes 0.000 claims description 162
• 108020003175 receptors Proteins 0.000 claims description 162
• 210000004027 cell Anatomy 0.000 claims description 160
• 102000040430 polynucleotide Human genes 0.000 claims description 151
• 108091033319 polynucleotide Proteins 0.000 claims description 151
• 239000002157 polynucleotide Substances 0.000 claims description 151
• 238000000034 method Methods 0.000 claims description 146
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 145
• 235000001014 amino acid Nutrition 0.000 claims description 142
• 150000001413 amino acids Chemical class 0.000 claims description 140
• 230000027455 binding Effects 0.000 claims description 131
• 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims description 118
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 115
• 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 86
• 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 84
• 108090000623 proteins and genes Proteins 0.000 claims description 83
• 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims description 78
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 77
• 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims description 74
• 108091008605 VEGF receptors Proteins 0.000 claims description 69
• 239000000203 mixture Substances 0.000 claims description 63
• 102000004169 proteins and genes Human genes 0.000 claims description 63
• 239000012634 fragment Substances 0.000 claims description 62
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 60
• 210000002889 endothelial cell Anatomy 0.000 claims description 59
• 235000018102 proteins Nutrition 0.000 claims description 57
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 54
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 53
• 239000002773 nucleotide Substances 0.000 claims description 50
• 125000003729 nucleotide group Chemical group 0.000 claims description 50
• 239000013598 vector Substances 0.000 claims description 49
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims description 47
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
• 239000003102 growth factor Substances 0.000 claims description 43
• 230000012010 growth Effects 0.000 claims description 39
• 239000003795 chemical substances by application Substances 0.000 claims description 36
• 239000003446 ligand Substances 0.000 claims description 32
• 150000001875 compounds Chemical class 0.000 claims description 31
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 29
• 241000282414 Homo sapiens Species 0.000 claims description 29
• 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 29
• 201000010099 disease Diseases 0.000 claims description 29
• 239000003814 drug Substances 0.000 claims description 28
• 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims description 25
• 230000000694 effects Effects 0.000 claims description 25
• 230000001404 mediated effect Effects 0.000 claims description 25
• 238000012216 screening Methods 0.000 claims description 25
• 238000012360 testing method Methods 0.000 claims description 25
• 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims description 24
• 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims description 22
• 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims description 22
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 22
• 230000010261 cell growth Effects 0.000 claims description 21
• 238000000338 in vitro Methods 0.000 claims description 21
• 108010029485 Protein Isoforms Proteins 0.000 claims description 20
• 102000001708 Protein Isoforms Human genes 0.000 claims description 20
• 238000004519 manufacturing process Methods 0.000 claims description 17
• 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 16
• 230000002401 inhibitory effect Effects 0.000 claims description 16
• 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 15
• 102000058223 human VEGFA Human genes 0.000 claims description 15
• 239000003112 inhibitor Substances 0.000 claims description 15
• 208000035475 disorder Diseases 0.000 claims description 14
• 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 14
• 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims description 13
• 102100035194 Placenta growth factor Human genes 0.000 claims description 13
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
• 125000000539 amino acid group Chemical group 0.000 claims description 12
• 230000003511 endothelial effect Effects 0.000 claims description 12
• 210000000130 stem cell Anatomy 0.000 claims description 12
• 241000124008 Mammalia Species 0.000 claims description 11
• 108010076504 Protein Sorting Signals Proteins 0.000 claims description 11
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 10
• 235000018417 cysteine Nutrition 0.000 claims description 10
• 239000013604 expression vector Substances 0.000 claims description 10
• 230000001105 regulatory effect Effects 0.000 claims description 10
• 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims description 10
• 230000004936 stimulating effect Effects 0.000 claims description 9
• 230000004913 activation Effects 0.000 claims description 8
• 230000008859 change Effects 0.000 claims description 8
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 claims description 7
• 229940079593 drug Drugs 0.000 claims description 7
• 208000002502 lymphedema Diseases 0.000 claims description 7
• 239000002243 precursor Substances 0.000 claims description 7
• 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 claims description 6
• 206010025282 Lymphoedema Diseases 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 6
• 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 6
• 238000002156 mixing Methods 0.000 claims description 6
• 208000024891 symptom Diseases 0.000 claims description 6
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 5
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 5
• 230000035755 proliferation Effects 0.000 claims description 5
• 210000001185 bone marrow Anatomy 0.000 claims description 4
• 210000002826 placenta Anatomy 0.000 claims description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
• 230000006798 recombination Effects 0.000 claims description 3
• 238000005215 recombination Methods 0.000 claims description 3
• 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 claims description 2
• 108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 claims description 2
• 230000004069 differentiation Effects 0.000 claims description 2
• 230000011132 hemopoiesis Effects 0.000 claims description 2
• 102000058241 human VEGFB Human genes 0.000 claims description 2
• 102000058238 human VEGFC Human genes 0.000 claims description 2
• 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 claims 17
• 108010082093 Placenta Growth Factor Proteins 0.000 claims 1
• 102100040681 Platelet-derived growth factor C Human genes 0.000 claims 1
• 102000050995 human FLT1 Human genes 0.000 claims 1
• 108010017992 platelet-derived growth factor C Proteins 0.000 claims 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 134
• 229940024606 amino acid Drugs 0.000 description 79
• 230000014509 gene expression Effects 0.000 description 66
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 58
• 206010028980 Neoplasm Diseases 0.000 description 49
• 108020004414 DNA Proteins 0.000 description 36
• 238000011282 treatment Methods 0.000 description 35
• 210000001519 tissue Anatomy 0.000 description 33
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 30
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 30
• 230000001225 therapeutic effect Effects 0.000 description 29
• 230000033115 angiogenesis Effects 0.000 description 28
• 238000001727 in vivo Methods 0.000 description 21
• 239000013615 primer Substances 0.000 description 21
• 210000004204 blood vessel Anatomy 0.000 description 20
• 230000011664 signaling Effects 0.000 description 19
• 201000011510 cancer Diseases 0.000 description 17
• 239000002502 liposome Substances 0.000 description 17
• 241000699670 Mus sp. Species 0.000 description 16
• 108091006116 chimeric peptides Proteins 0.000 description 16
• 230000008569 process Effects 0.000 description 13
• 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 12
• 108091028043 Nucleic acid sequence Proteins 0.000 description 12
• 208000031481 Pathologic Constriction Diseases 0.000 description 12
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 12
• 230000006870 function Effects 0.000 description 12
• 230000035772 mutation Effects 0.000 description 12
• 102000039446 nucleic acids Human genes 0.000 description 12
• 108020004707 nucleic acids Proteins 0.000 description 12
• 150000007523 nucleic acids Chemical class 0.000 description 12
• 208000037803 restenosis Diseases 0.000 description 12
• 230000036262 stenosis Effects 0.000 description 12
• 208000037804 stenosis Diseases 0.000 description 12
• 241000701161 unidentified adenovirus Species 0.000 description 12
• 230000002792 vascular Effects 0.000 description 12
• 230000003612 virological effect Effects 0.000 description 12
• 108700019146 Transgenes Proteins 0.000 description 11
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
• 241000700605 Viruses Species 0.000 description 11
• 230000015572 biosynthetic process Effects 0.000 description 11
• 229960004316 cisplatin Drugs 0.000 description 11
• 239000002299 complementary DNA Substances 0.000 description 11
• 230000004927 fusion Effects 0.000 description 11
• 238000001415 gene therapy Methods 0.000 description 11
• 238000009396 hybridization Methods 0.000 description 11
• 230000001965 increasing effect Effects 0.000 description 11
• 238000013508 migration Methods 0.000 description 11
• 239000013612 plasmid Substances 0.000 description 11
• 239000000243 solution Substances 0.000 description 11
• 238000012546 transfer Methods 0.000 description 11
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
• 102000005720 Glutathione transferase Human genes 0.000 description 10
• 108010070675 Glutathione transferase Proteins 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 10
• 238000000137 annealing Methods 0.000 description 10
• 230000002950 deficient Effects 0.000 description 10
• 230000018109 developmental process Effects 0.000 description 10
• 238000012986 modification Methods 0.000 description 10
• 238000002560 therapeutic procedure Methods 0.000 description 10
• 210000004881 tumor cell Anatomy 0.000 description 10
• 238000011144 upstream manufacturing Methods 0.000 description 10
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 9
• 102000004207 Neuropilin-1 Human genes 0.000 description 9
• 108090000772 Neuropilin-1 Proteins 0.000 description 9
• 108091008606 PDGF receptors Proteins 0.000 description 9
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 9
• 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 9
• 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 9
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
• 230000004071 biological effect Effects 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 238000011161 development Methods 0.000 description 9
• 102000037865 fusion proteins Human genes 0.000 description 9
• 108020001507 fusion proteins Proteins 0.000 description 9
• 238000003384 imaging method Methods 0.000 description 9
• 210000001365 lymphatic vessel Anatomy 0.000 description 9
• 239000002609 medium Substances 0.000 description 9
• 230000005012 migration Effects 0.000 description 9
• 230000004048 modification Effects 0.000 description 9
• 238000006467 substitution reaction Methods 0.000 description 9
• 241000894006 Bacteria Species 0.000 description 8
• 108091026890 Coding region Proteins 0.000 description 8
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 238000003780 insertion Methods 0.000 description 8
• 230000037431 insertion Effects 0.000 description 8
• 229920000642 polymer Polymers 0.000 description 8
• 230000000638 stimulation Effects 0.000 description 8
• 238000003786 synthesis reaction Methods 0.000 description 8
• 208000007766 Kaposi sarcoma Diseases 0.000 description 7
• 102000004213 Neuropilin-2 Human genes 0.000 description 7
• 108090000770 Neuropilin-2 Proteins 0.000 description 7
• 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 7
• 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 7
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 7
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 230000007423 decrease Effects 0.000 description 7
• 229960005420 etoposide Drugs 0.000 description 7
• 239000000833 heterodimer Substances 0.000 description 7
• 210000004072 lung Anatomy 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 230000001394 metastastic effect Effects 0.000 description 7
• 206010061289 metastatic neoplasm Diseases 0.000 description 7
• 230000001613 neoplastic effect Effects 0.000 description 7
• 239000002245 particle Substances 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• 230000014616 translation Effects 0.000 description 7
• 102000003390 tumor necrosis factor Human genes 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 206010006187 Breast cancer Diseases 0.000 description 6
• 208000026310 Breast neoplasm Diseases 0.000 description 6
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 6
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 6
• 108010041308 Endothelial Growth Factors Proteins 0.000 description 6
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
• 208000034578 Multiple myelomas Diseases 0.000 description 6
• 206010035226 Plasma cell myeloma Diseases 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 238000010494 dissociation reaction Methods 0.000 description 6
• 230000005593 dissociations Effects 0.000 description 6
• 210000002744 extracellular matrix Anatomy 0.000 description 6
• 229960002949 fluorouracil Drugs 0.000 description 6
• 230000001976 improved effect Effects 0.000 description 6
• 238000001802 infusion Methods 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 210000003734 kidney Anatomy 0.000 description 6
• 230000035168 lymphangiogenesis Effects 0.000 description 6
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 6
• 230000001737 promoting effect Effects 0.000 description 6
• 230000000306 recurrent effect Effects 0.000 description 6
• 230000010076 replication Effects 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 230000008728 vascular permeability Effects 0.000 description 6
• 210000005166 vasculature Anatomy 0.000 description 6
• 208000005623 Carcinogenesis Diseases 0.000 description 5
• 102000000844 Cell Surface Receptors Human genes 0.000 description 5
• 108010001857 Cell Surface Receptors Proteins 0.000 description 5
• 230000005778 DNA damage Effects 0.000 description 5
• 231100000277 DNA damage Toxicity 0.000 description 5
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
• 229920002971 Heparan sulfate Polymers 0.000 description 5
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
• 206010029113 Neovascularisation Diseases 0.000 description 5
• 101000830383 Oryctolagus cuniculus Corticostatin-3 Proteins 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• 230000002159 abnormal effect Effects 0.000 description 5
• 238000007792 addition Methods 0.000 description 5
• 238000002399 angioplasty Methods 0.000 description 5
• 239000005557 antagonist Substances 0.000 description 5
• 239000002246 antineoplastic agent Substances 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• 230000017531 blood circulation Effects 0.000 description 5
• 230000036952 cancer formation Effects 0.000 description 5
• 231100000504 carcinogenesis Toxicity 0.000 description 5
• 230000004087 circulation Effects 0.000 description 5
• 238000002648 combination therapy Methods 0.000 description 5
• 230000000295 complement effect Effects 0.000 description 5
• 230000000875 corresponding effect Effects 0.000 description 5
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
• 229940127089 cytotoxic agent Drugs 0.000 description 5
• 239000003085 diluting agent Substances 0.000 description 5
• 239000003623 enhancer Substances 0.000 description 5
• 230000008175 fetal development Effects 0.000 description 5
• 210000003754 fetus Anatomy 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 210000002216 heart Anatomy 0.000 description 5
• 229960002897 heparin Drugs 0.000 description 5
• 239000000017 hydrogel Substances 0.000 description 5
• 238000001990 intravenous administration Methods 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 210000004962 mammalian cell Anatomy 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 108020004999 messenger RNA Proteins 0.000 description 5
• 230000008747 mitogenic response Effects 0.000 description 5
• 229960004857 mitomycin Drugs 0.000 description 5
• 210000001616 monocyte Anatomy 0.000 description 5
• 230000003525 myelopoietic effect Effects 0.000 description 5
• 230000009826 neoplastic cell growth Effects 0.000 description 5
• 210000000440 neutrophil Anatomy 0.000 description 5
• 230000010412 perfusion Effects 0.000 description 5
• 230000026731 phosphorylation Effects 0.000 description 5
• 238000006366 phosphorylation reaction Methods 0.000 description 5
• -1 polyoxyethylene Polymers 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 230000002797 proteolythic effect Effects 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 230000005855 radiation Effects 0.000 description 5
• 238000001959 radiotherapy Methods 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 210000003491 skin Anatomy 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 238000001356 surgical procedure Methods 0.000 description 5
• 210000003556 vascular endothelial cell Anatomy 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• 201000009030 Carcinoma Diseases 0.000 description 4
• 108020004705 Codon Proteins 0.000 description 4
• 108010092160 Dactinomycin Proteins 0.000 description 4
• 102000003886 Glycoproteins Human genes 0.000 description 4
• 108090000288 Glycoproteins Proteins 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 206010025323 Lymphomas Diseases 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
• 108091034117 Oligonucleotide Proteins 0.000 description 4
• 102000035195 Peptidases Human genes 0.000 description 4
• 108091005804 Peptidases Proteins 0.000 description 4
• 239000004365 Protease Substances 0.000 description 4
• 201000004681 Psoriasis Diseases 0.000 description 4
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 4
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 4
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 230000012292 cell migration Effects 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 238000004587 chromatography analysis Methods 0.000 description 4
• 210000004351 coronary vessel Anatomy 0.000 description 4
• 150000001945 cysteines Chemical class 0.000 description 4
• 229960000640 dactinomycin Drugs 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
• 210000003038 endothelium Anatomy 0.000 description 4
• 230000001605 fetal effect Effects 0.000 description 4
• 230000013595 glycosylation Effects 0.000 description 4
• 238000006206 glycosylation reaction Methods 0.000 description 4
• 230000001771 impaired effect Effects 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 230000000302 ischemic effect Effects 0.000 description 4
• 210000001165 lymph node Anatomy 0.000 description 4
• 230000001926 lymphatic effect Effects 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 230000009401 metastasis Effects 0.000 description 4
• 210000003739 neck Anatomy 0.000 description 4
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
• 210000001672 ovary Anatomy 0.000 description 4
• 238000010647 peptide synthesis reaction Methods 0.000 description 4
• 239000002953 phosphate buffered saline Substances 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• 230000029663 wound healing Effects 0.000 description 4
• SGDBTWWWUNNDEQ-GFCCVEGCSA-N (2r)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)[C@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-GFCCVEGCSA-N 0.000 description 3
• KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 3
• 108010006654 Bleomycin Proteins 0.000 description 3
• 208000003174 Brain Neoplasms Diseases 0.000 description 3
• 108091033380 Coding strand Proteins 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 102000015696 Interleukins Human genes 0.000 description 3
• 108010063738 Interleukins Proteins 0.000 description 3
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 108091061960 Naked DNA Proteins 0.000 description 3
• 206010030113 Oedema Diseases 0.000 description 3
• 101710182846 Polyhedrin Proteins 0.000 description 3
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 206010039491 Sarcoma Diseases 0.000 description 3
• 238000012300 Sequence Analysis Methods 0.000 description 3
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
• 230000035508 accumulation Effects 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 229940009456 adriamycin Drugs 0.000 description 3
• 206010064930 age-related macular degeneration Diseases 0.000 description 3
• 150000001408 amides Chemical group 0.000 description 3
• 230000002491 angiogenic effect Effects 0.000 description 3
• 230000001772 anti-angiogenic effect Effects 0.000 description 3
• 230000000259 anti-tumor effect Effects 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 108010084541 asialoorosomucoid Proteins 0.000 description 3
• 230000008827 biological function Effects 0.000 description 3
• 229960001561 bleomycin Drugs 0.000 description 3
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
• 210000000481 breast Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 230000002526 effect on cardiovascular system Effects 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 230000002349 favourable effect Effects 0.000 description 3
• 238000013467 fragmentation Methods 0.000 description 3
• 238000006062 fragmentation reaction Methods 0.000 description 3
• 239000003966 growth inhibitor Substances 0.000 description 3
• 208000014829 head and neck neoplasm Diseases 0.000 description 3
• 229920000669 heparin Polymers 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 239000000710 homodimer Substances 0.000 description 3
• 239000012216 imaging agent Substances 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 229940047122 interleukins Drugs 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 208000028867 ischemia Diseases 0.000 description 3
• 231100000518 lethal Toxicity 0.000 description 3
• 230000001665 lethal effect Effects 0.000 description 3
• 210000001077 lymphatic endothelium Anatomy 0.000 description 3
• 208000002780 macular degeneration Diseases 0.000 description 3
• 230000014759 maintenance of location Effects 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 210000003584 mesangial cell Anatomy 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 208000031225 myocardial ischemia Diseases 0.000 description 3
• 210000005170 neoplastic cell Anatomy 0.000 description 3
• 229940127084 other anti-cancer agent Drugs 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 210000003668 pericyte Anatomy 0.000 description 3
• 230000035699 permeability Effects 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 230000008488 polyadenylation Effects 0.000 description 3
• NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 238000011321 prophylaxis Methods 0.000 description 3
• 210000002307 prostate Anatomy 0.000 description 3
• 238000003259 recombinant expression Methods 0.000 description 3
• 108091008146 restriction endonucleases Proteins 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 238000012163 sequencing technique Methods 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 230000002381 testicular Effects 0.000 description 3
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 238000002054 transplantation Methods 0.000 description 3
• 230000005747 tumor angiogenesis Effects 0.000 description 3
• 230000005740 tumor formation Effects 0.000 description 3
• 230000004614 tumor growth Effects 0.000 description 3
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
• 230000006459 vascular development Effects 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
• 229960004528 vincristine Drugs 0.000 description 3
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 108010025188 Alcohol oxidase Proteins 0.000 description 2
• 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
• 208000004652 Cardiovascular Abnormalities Diseases 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 206010052358 Colorectal cancer metastatic Diseases 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• 239000012623 DNA damaging agent Substances 0.000 description 2
• 230000004543 DNA replication Effects 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 102400001301 Gasdermin-B, C-terminal Human genes 0.000 description 2
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
• 208000032612 Glial tumor Diseases 0.000 description 2
• 206010018338 Glioma Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 102100037907 High mobility group protein B1 Human genes 0.000 description 2
• 101710168537 High mobility group protein B1 Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 2
• 241000270322 Lepidosauria Species 0.000 description 2
• 206010025219 Lymphangioma Diseases 0.000 description 2
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
• 101600105505 Mus musculus Vascular endothelial growth factor C (isoform 1) Proteins 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
• 101100449758 Onchocerca volvulus GST1 gene Proteins 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 241000700635 Orf virus Species 0.000 description 2
• 101001041615 Oryctolagus cuniculus Corticostatin-4 Proteins 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 2
• 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 108010067787 Proteoglycans Proteins 0.000 description 2
• 102000016611 Proteoglycans Human genes 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 108050003978 Semaphorin Proteins 0.000 description 2
• 102000014105 Semaphorin Human genes 0.000 description 2
• 102000013008 Semaphorin-3A Human genes 0.000 description 2
• 108010090319 Semaphorin-3A Proteins 0.000 description 2
• 229920005654 Sephadex Polymers 0.000 description 2
• 239000012507 Sephadex™ Substances 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• 241000256248 Spodoptera Species 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 description 2
• 241000255985 Trichoplusia Species 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 239000004037 angiogenesis inhibitor Substances 0.000 description 2
• 238000005571 anion exchange chromatography Methods 0.000 description 2
• RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
• 238000011319 anticancer therapy Methods 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 230000001588 bifunctional effect Effects 0.000 description 2
• 230000031018 biological processes and functions Effects 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 201000008275 breast carcinoma Diseases 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
• 229940127093 camptothecin Drugs 0.000 description 2
• FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
• 229960003669 carbenicillin Drugs 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 230000021523 carboxylation Effects 0.000 description 2
• 238000006473 carboxylation reaction Methods 0.000 description 2
• 230000007555 cardiovascular defect Effects 0.000 description 2
• 230000008209 cardiovascular development Effects 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 230000035605 chemotaxis Effects 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 229960004630 chlorambucil Drugs 0.000 description 2
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 238000004590 computer program Methods 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 231100000599 cytotoxic agent Toxicity 0.000 description 2
• GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 238000002059 diagnostic imaging Methods 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 108010052305 exodeoxyribonuclease III Proteins 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 238000001476 gene delivery Methods 0.000 description 2
• 238000010363 gene targeting Methods 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 206010020718 hyperplasia Diseases 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 239000003999 initiator Substances 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 229910052742 iron Inorganic materials 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 230000002147 killing effect Effects 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• 201000002818 limb ischemia Diseases 0.000 description 2
• 230000029226 lipidation Effects 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 210000002751 lymph Anatomy 0.000 description 2
• 210000005073 lymphatic endothelial cell Anatomy 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 229960004961 mechlorethamine Drugs 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 229960001924 melphalan Drugs 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• 230000002297 mitogenic effect Effects 0.000 description 2
• 230000011278 mitosis Effects 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 210000004179 neuropil Anatomy 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 239000007800 oxidant agent Substances 0.000 description 2
• 230000001590 oxidative effect Effects 0.000 description 2
• 210000003254 palate Anatomy 0.000 description 2
• 230000003076 paracrine Effects 0.000 description 2
• 230000005298 paramagnetic effect Effects 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 239000000902 placebo Substances 0.000 description 2
• 229940068196 placebo Drugs 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 230000035935 pregnancy Effects 0.000 description 2
• 230000002028 premature Effects 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000003362 replicative effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 210000002027 skeletal muscle Anatomy 0.000 description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 2
• 238000000527 sonication Methods 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• 229960003433 thalidomide Drugs 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 241000701447 unidentified baculovirus Species 0.000 description 2
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
• 210000004291 uterus Anatomy 0.000 description 2
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
• 230000029812 viral genome replication Effects 0.000 description 2
• PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 1
• GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 description 1
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
• DLZKEQQWXODGGZ-KCJUWKMLSA-N 2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KCJUWKMLSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• 201000010000 Agranulocytosis Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 208000004375 Angiodysplasia Diseases 0.000 description 1
• 241000269350 Anura Species 0.000 description 1
• 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
• 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
• 108010039627 Aprotinin Proteins 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 108700020463 BRCA1 Proteins 0.000 description 1
• 102000036365 BRCA1 Human genes 0.000 description 1
• 101150072950 BRCA1 gene Proteins 0.000 description 1
• 108010001478 Bacitracin Proteins 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 108010081589 Becaplermin Proteins 0.000 description 1
• 102100037674 Bis(5'-adenosyl)-triphosphatase Human genes 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010048962 Brain oedema Diseases 0.000 description 1
• 101800001415 Bri23 peptide Proteins 0.000 description 1
• 102400000107 C-terminal peptide Human genes 0.000 description 1
• 101800000655 C-terminal peptide Proteins 0.000 description 1
• 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• 101800005309 Carboxy-terminal peptide Proteins 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 239000005496 Chlorsulfuron Substances 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 108010074466 Chromosomal Puffs Proteins 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 101710094648 Coat protein Proteins 0.000 description 1
• 102000029816 Collagenase Human genes 0.000 description 1
• 108060005980 Collagenase Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 108090000056 Complement factor B Proteins 0.000 description 1
• 102000003712 Complement factor B Human genes 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 206010010535 Congenital lymphoedema Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
• JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
• 101710112752 Cytotoxin Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
• 229920002271 DEAE-Sepharose Polymers 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 239000012624 DNA alkylating agent Substances 0.000 description 1
• 239000003155 DNA primer Substances 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 229910052692 Dysprosium Inorganic materials 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 229910052691 Erbium Inorganic materials 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
• 208000001951 Fetal Death Diseases 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 206010055690 Foetal death Diseases 0.000 description 1
• 229910052688 Gadolinium Inorganic materials 0.000 description 1
• 102000053187 Glucuronidase Human genes 0.000 description 1
• 108010060309 Glucuronidase Proteins 0.000 description 1
• 108010007979 Glycocholic Acid Proteins 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
• 206010018687 Granulocytopenia Diseases 0.000 description 1
• 102000012428 Hematopoietic Cell Growth Factors Human genes 0.000 description 1
• 108010022580 Hematopoietic Cell Growth Factors Proteins 0.000 description 1
• 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
• 108010022901 Heparin Lyase Proteins 0.000 description 1
• 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
• 102100022130 High mobility group protein B3 Human genes 0.000 description 1
• 101001006375 Homo sapiens High mobility group nucleosome-binding domain-containing protein 4 Proteins 0.000 description 1
• 101001045794 Homo sapiens High mobility group protein B3 Proteins 0.000 description 1
• 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
• 101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 description 1
• 108010000521 Human Growth Hormone Proteins 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102100039064 Interleukin-3 Human genes 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 206010022562 Intermittent claudication Diseases 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 102100038609 Lactoperoxidase Human genes 0.000 description 1
• 108010023244 Lactoperoxidase Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 239000000232 Lipid Bilayer Substances 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000018501 Lymphatic disease Diseases 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 101710125418 Major capsid protein Proteins 0.000 description 1
• 206010025476 Malabsorption Diseases 0.000 description 1
• WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108010024777 Mating Factor Receptors Proteins 0.000 description 1
• IMTUWVJPCQPJEE-IUCAKERBSA-N Met-Lys Chemical group CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN IMTUWVJPCQPJEE-IUCAKERBSA-N 0.000 description 1
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
• 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
• 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 208000004221 Multiple Trauma Diseases 0.000 description 1
• 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
• 208000023637 Multiple injury Diseases 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 241000711408 Murine respirovirus Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 201000009623 Myopathy Diseases 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• 102000002111 Neuropilin Human genes 0.000 description 1
• 108050009450 Neuropilin Proteins 0.000 description 1
• VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 101710141454 Nucleoprotein Proteins 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
• 206010034576 Peripheral ischaemia Diseases 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
• 108010001014 Plasminogen Activators Proteins 0.000 description 1
• 102000001938 Plasminogen Activators Human genes 0.000 description 1
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 108010076039 Polyproteins Proteins 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 101710083689 Probable capsid protein Proteins 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
• 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
• 206010038111 Recurrent cancer Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 206010038934 Retinopathy proliferative Diseases 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 239000012506 Sephacryl® Substances 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
• UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
• 241000862969 Stella Species 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 241000521327 Streptomyces caespitosus Species 0.000 description 1
• 241001147844 Streptomyces verticillus Species 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 208000002847 Surgical Wound Diseases 0.000 description 1
• 108090000054 Syndecan-2 Proteins 0.000 description 1
• 241000202349 Taxus brevifolia Species 0.000 description 1
• GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
• 229910052771 Terbium Inorganic materials 0.000 description 1
• 101001081186 Tetrahymena pyriformis High mobility group protein Proteins 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
• 241000723873 Tobacco mosaic virus Species 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
• 206010053648 Vascular occlusion Diseases 0.000 description 1
• 108020005202 Viral DNA Proteins 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 102100022748 Wilms tumor protein Human genes 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 229910052769 Ytterbium Inorganic materials 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 238000010306 acid treatment Methods 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229940098174 alkeran Drugs 0.000 description 1
• 210000001643 allantois Anatomy 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 238000003277 amino acid sequence analysis Methods 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 210000002403 aortic endothelial cell Anatomy 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 229960004405 aprotinin Drugs 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229910052789 astatine Inorganic materials 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• 230000004009 axon guidance Effects 0.000 description 1
• 229960003071 bacitracin Drugs 0.000 description 1
• 229930184125 bacitracin Natural products 0.000 description 1
• CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 239000003012 bilayer membrane Substances 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000008275 binding mechanism Effects 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 238000006065 biodegradation reaction Methods 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 108010005713 bis(5'-adenosyl)triphosphatase Proteins 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 239000003114 blood coagulation factor Substances 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 208000006752 brain edema Diseases 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 201000002142 breast rhabdomyosarcoma Diseases 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 238000005277 cation exchange chromatography Methods 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 230000008619 cell matrix interaction Effects 0.000 description 1
• 230000009134 cell regulation Effects 0.000 description 1
• 230000010307 cell transformation Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 201000005667 central retinal vein occlusion Diseases 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 230000009920 chelation Effects 0.000 description 1
• ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 108700010039 chimeric receptor Proteins 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 239000011651 chromium Substances 0.000 description 1
• BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 210000003799 chromosomal puff Anatomy 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000024321 chromosome segregation Effects 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 238000012761 co-transfection Methods 0.000 description 1
• 229910017052 cobalt Inorganic materials 0.000 description 1
• 239000010941 cobalt Substances 0.000 description 1
• XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229960002424 collagenase Drugs 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 229940047120 colony stimulating factors Drugs 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
• 230000002301 combined effect Effects 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000002872 contrast media Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 229920001577 copolymer Chemical compound 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 238000007887 coronary angioplasty Methods 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 239000013058 crude material Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 239000003145 cytotoxic factor Substances 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 230000004041 dendritic cell maturation Effects 0.000 description 1
• 210000004207 dermis Anatomy 0.000 description 1
• 230000009547 development abnormality Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 230000000447 dimerizing effect Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
• 238000002635 electroconvulsive therapy Methods 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 230000035194 endochondral ossification Effects 0.000 description 1
• 230000009762 endothelial cell differentiation Effects 0.000 description 1
• 230000008753 endothelial function Effects 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 210000002409 epiglottis Anatomy 0.000 description 1
• YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 238000001400 expression cloning Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 210000004996 female reproductive system Anatomy 0.000 description 1
• 210000004700 fetal blood Anatomy 0.000 description 1
• 231100000479 fetal death Toxicity 0.000 description 1
• 230000000893 fibroproliferative effect Effects 0.000 description 1
• 239000010419 fine particle Substances 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
• 229910052733 gallium Inorganic materials 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• 238000001641 gel filtration chromatography Methods 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 1
• 210000004195 gingiva Anatomy 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• CBMIPXHVOVTTTL-UHFFFAOYSA-N gold(3+) Chemical compound [Au+3] CBMIPXHVOVTTTL-UHFFFAOYSA-N 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 210000004349 growth plate Anatomy 0.000 description 1
• 229940029575 guanosine Drugs 0.000 description 1
• 235000015220 hamburgers Nutrition 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000003067 hemagglutinative effect Effects 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 238000005734 heterodimerization reaction Methods 0.000 description 1
• 101150113423 hisD gene Proteins 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• SCKNFLZJSOHWIV-UHFFFAOYSA-N holmium(3+) Chemical compound [Ho+3] SCKNFLZJSOHWIV-UHFFFAOYSA-N 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000051543 human VEGFD Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 210000003000 inclusion body Anatomy 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 238000009830 intercalation Methods 0.000 description 1
• 230000008611 intercellular interaction Effects 0.000 description 1
• 229940076264 interleukin-3 Drugs 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 208000021156 intermittent vascular claudication Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 230000001678 irradiating effect Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 229940057428 lactoperoxidase Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• CZMAIROVPAYCMU-UHFFFAOYSA-N lanthanum(3+) Chemical compound [La+3] CZMAIROVPAYCMU-UHFFFAOYSA-N 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 208000027884 letterer-Siwe disease Diseases 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 229940049918 linoleate Drugs 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 239000004973 liquid crystal related substance Substances 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 230000000938 luteal effect Effects 0.000 description 1
• 208000018555 lymphatic system disease Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 230000022275 macrophage chemotaxis Effects 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000005291 magnetic effect Effects 0.000 description 1
• 210000004995 male reproductive system Anatomy 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000006178 malignant mesothelioma Diseases 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
• 229950008959 marimastat Drugs 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 210000003593 megakaryocyte Anatomy 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 208000021039 metastatic melanoma Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 230000028550 monocyte chemotaxis Effects 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 230000023105 myelination Effects 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 210000001989 nasopharynx Anatomy 0.000 description 1
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
• QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
• 230000009707 neogenesis Effects 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 210000000933 neural crest Anatomy 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000013631 noncovalent dimer Substances 0.000 description 1
• 230000000683 nonmetastatic effect Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000001668 nucleic acid synthesis Methods 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 230000005305 organ development Effects 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 210000001711 oxyntic cell Anatomy 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 210000003899 penis Anatomy 0.000 description 1
• 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 238000009521 phase II clinical trial Methods 0.000 description 1
• 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
• 208000001297 phlebitis Diseases 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 229940012957 plasmin Drugs 0.000 description 1
• 229940127126 plasminogen activator Drugs 0.000 description 1
• 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
• YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
• 229960001237 podophyllotoxin Drugs 0.000 description 1
• YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920002704 polyhistidine Polymers 0.000 description 1
• 229920006254 polymer film Polymers 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 230000009596 postnatal growth Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 210000004777 protein coat Anatomy 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 230000003439 radiotherapeutic effect Effects 0.000 description 1
• 108091006084 receptor activators Proteins 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 238000001525 receptor binding assay Methods 0.000 description 1
• 108091006082 receptor inhibitors Proteins 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000026267 regulation of growth Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 125000006853 reporter group Chemical group 0.000 description 1
• 210000005000 reproductive tract Anatomy 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000004263 retinal angiogenesis Effects 0.000 description 1
• 230000004491 retinal development Effects 0.000 description 1
• 208000004644 retinal vein occlusion Diseases 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 229910052702 rhenium Inorganic materials 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 239000012146 running buffer Substances 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 229910052711 selenium Inorganic materials 0.000 description 1
• 239000011669 selenium Substances 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 231100001055 skeletal defect Toxicity 0.000 description 1
• 230000007958 sleep Effects 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 235000009518 sodium iodide Nutrition 0.000 description 1
• OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 229950001248 squalamine Drugs 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000012916 structural analysis Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 238000010863 targeted diagnosis Methods 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 229910052713 technetium Inorganic materials 0.000 description 1
• 229940056501 technetium 99m Drugs 0.000 description 1
• GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
• 238000011191 terminal modification Methods 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 230000003813 thin hair Effects 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• 229960003766 thrombin (human) Drugs 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 238000012090 tissue culture technique Methods 0.000 description 1
• 210000002105 tongue Anatomy 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 210000002993 trophoblast Anatomy 0.000 description 1
• 101150081616 trpB gene Proteins 0.000 description 1
• 101150111232 trpB-1 gene Proteins 0.000 description 1
• 230000004565 tumor cell growth Effects 0.000 description 1
• WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 239000010937 tungsten Substances 0.000 description 1
• 238000010396 two-hybrid screening Methods 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
• 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 229910052720 vanadium Inorganic materials 0.000 description 1
• LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
• 208000021331 vascular occlusion disease Diseases 0.000 description 1
• 230000032665 vasculature development Effects 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 229960001722 verapamil Drugs 0.000 description 1
• 210000003501 vero cell Anatomy 0.000 description 1
• 230000007332 vesicle formation Effects 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 210000003905 vulva Anatomy 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1